{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Yu EM"],"pubmed_abstract":["Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways."],"journal":["Research and reports in urology"],"pagination":["519-529"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10693764"],"repository":["biostudies-literature"],"pubmed_title":["Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities."],"pmcid":["PMC10693764"],"pubmed_authors":["Hwang MW","Yu EM","Aragon-Ching JB"],"additional_accession":[]},"is_claimable":false,"name":"Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.","description":"Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-25T17:25:14.911Z","creation":"2025-04-06T04:05:33.644Z"},"accession":"S-EPMC10693764","cross_references":{"pubmed":["38050587"],"doi":["10.2147/RRU.S386517"]}}